The Patent Finder
YR

Yeda Research and Development Co. Ltd.

Filings on record here from 2001, where this site's data begins
OverviewNotableFeesChangesFamiliesPatent listSources & methods

281 patents currently held

36 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
3 more records may belong here and await a decision; they are not counted.

The next term ends in Dec 2026. from the record

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
28
Ending by 2030
Dec 2026
Next term end
175
Patent families

When these terms end

Held patents by the year their term ends
notable patents fee due within 90 days all others Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.

Notable patents

Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Reducing Systemic Regulatory T Cell Levels or Activity for Treatment of Disease and Injury of the CNS US 9,856,318
Cited by 74 later US patents, top 5% of utility patents granted in 2018 in our data, and renewed at every maintenance window due so far. Protection runs to 2035. A terminal disclaimer caps this term to an earlier patent's.
Ends Mar 2035 · High confidence
Also notable
Compositions and Methods for Treating Malignant, Autoimmune and Inflammatory Diseases US 10,828,318
Cited by 47 later US patents, top 5% of utility patents granted in 2020 in our data. Protection runs to 2037.
Ends Jan 2037 · High confidence
Also notable
Plant with Altered Content of Steroidal Alkaloids US 10,806,119
Cited by 27 later US patents, top 10% of utility patents granted in 2020 in our data. Protection runs to 2034.
Ends Jun 2034 · High confidence

Formerly held, still cited

Notable
The most cited patent in this portfolio, cited by 167 later US patents, top 5% of utility patents granted in 2011 in our data. Protection runs to 2028.
now held by Brainsway, Ltd.
Ends Jul 2028 · High confidence

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 6 fees due Dec 2 to 30, 2026 · next Dec 2
  • 2 fees due Jan 2 to 23, 2027 · next Jan 2
  • 5 fees due Feb 6 to 22, 2027 · next Feb 6
  • 3 fees due Mar 5 to 19, 2027 · next Mar 5
  • 10 fees due Apr 1 to 29, 2027 · next Apr 1
  • 4 fees due May 3 to 19, 2027 · next May 3
  • 10 fees due Jun 5 to 30, 2027 · next Jun 5
  • 8 fees due Jul 7 to 30, 2027 · next Jul 7
  • 10 fees due Aug 4 to 20, 2027 · next Aug 4
  • 6 fees due Sep 5 to 22, 2027 · next Sep 5
  • 9 fees due Oct 2 to 30, 2027 · next Oct 2
  • 2 fees due Nov 7 to 14, 2027 · next Nov 7

Which patents, and when each one lapses · Pro

Recent changes

What they patent

The largest of its 175 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
Reducing Systemic Regulatory T Cell Levels or Activity for Treatment of Disease and Injury of the CNS20 in forceto Aug 2036
Multiple Cavity-Coupled Emitters for Generating a Graph State10 in forceto Jul 2042
Plant with Altered Content of Steroidal Glycoalkaloids5 in forceto Jun 2034
Method and Apparatus for Predicting Response to Food4 in forceto Jul 2036
Micro-RNAs and Compositions Comprising Same for the Treatment and Diagnosis of Serotonin-, Adrenalin-, Noradrenalin-, Glutamate-, and Corticotropin-Releasing Hormone- Associated Medical Conditions (2014)4 in forceto Aug 2032

Patents held now

Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatusExpiresConfidence
US 8,388,954Stabilising Formulation for Immunoglobulin G Compositions in Liquid Form and in Lyophilised Form
In force
 · High confidence
In forceHigh confidence
US 7,897,840Salt Responsive Genes Useful for Generating Salt Resistant Transgenic Plants
In force
 · High confidence
In forceHigh confidence
US 10,258,651Methods of Generating Glial and Neuronal Cells and Use of Same for the Treatment of Medical Conditions of the CNS
In force
 · High confidence
In forceHigh confidence
US 11,406,670Methods of Generating Glial and Neuronal Cells and Use of Same for the Treatment of Medical Conditions of the CNS
In force
 · High confidence
In forceHigh confidence
US 10,689,415Conjugates of RGD Peptides and (BACTERIO)CHLOROPHYLL Photosensitizers
In force
 · Medium confidence
In forceMedium confidence
US 7,947,672Water-Soluble Anionic Bacteriochlorophyll Derivatives and Their Uses
In force
 · Medium confidence
In forceMedium confidence
US 8,067,008Peptide Inhibitors for Mediating Stress Responses
In force
 · High confidence
In forceHigh confidence
US 9,631,175Methods of Generating Glial and Neuronal Cells and Use of Same for the Treatment of Medical Conditions of the CNS
In force
 · High confidence
In forceHigh confidence
US 11,326,147Redirected, Genetically-Engineered T Regulatory Cells and Their Use in Suppression of Autoimmune and Inflammatory Disease
In force
 · High confidence
In forceHigh confidence
US 8,486,653Antibodies and Pharmaceutical Compositions Containing Same Useful for Inhibiting Activity of Metalloproteins
In force
 · Medium confidence
In forceMedium confidence
10 of 281 patents shown.
Pro members see all 281.
Pro members: see all 281 patents
Also on record, not counted in the 281: 36 patents in force now held by others · 343 patents ended · 203 applications pending · 472 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited